These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Vitamin K supplementation during oral anticoagulation: concerns. Stafford DW; Roberts HR; Vermeer C Blood; 2007 Apr; 109(8):3607; author reply 3607-8. PubMed ID: 17409344 [No Abstract] [Full Text] [Related]
25. Contributions of procoagulants and anticoagulants to the international normalized ratio and thrombin generation assay in patients treated with warfarin: potential role of protein Z as a powerful determinant of coagulation assays. Choi Q; Kim JE; Hyun J; Han KS; Kim HK Thromb Res; 2013 Jul; 132(1):e70-5. PubMed ID: 23769659 [TBL] [Abstract][Full Text] [Related]
26. Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment. Morimoto S; Fujioka Y; Tsutsumi C; Masai M; Okumura T; Yuba M; Sakoda T; Tsujino T; Ohyanagi M Am J Med Sci; 2005 Apr; 329(4):211-3. PubMed ID: 15832106 [TBL] [Abstract][Full Text] [Related]
28. Clinical impact of temporary therapy interruptions on anticoagulation control in patients treated with warfarin. Boros ML; Rybarczyk AM; Gallegos PJ; Zimmerman JP Am J Ther; 2013; 20(3):267-74. PubMed ID: 23011173 [TBL] [Abstract][Full Text] [Related]
29. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. Ageno W; Garcia D; Silingardi M; Galli M; Crowther M J Am Coll Cardiol; 2005 Aug; 46(4):732-3. PubMed ID: 16098445 [No Abstract] [Full Text] [Related]
30. Interaction between warfarin and topical miconazole cream. Devaraj A; O'Beirne JP; Veasey R; Dunk AA BMJ; 2002 Jul; 325(7355):77. PubMed ID: 12114237 [No Abstract] [Full Text] [Related]
31. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. Olukoga AO J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008 [No Abstract] [Full Text] [Related]
32. Update on coagulopathies. Schardt-Sacco D Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Nov; 90(5):559-63. PubMed ID: 11077376 [No Abstract] [Full Text] [Related]
33. Predicting the dose of warfarin for therapeutic anticoagulation. Sharma NK; Routledge PA; Rawlins MD; Davies DM Thromb Haemost; 1982 Jun; 47(3):230-1. PubMed ID: 7112495 [TBL] [Abstract][Full Text] [Related]
35. [Circulatory disorders]. van der Kuy A; van den Bemd AA; Beysens AJ Tijdschr Ziekenverpl; 1976 Apr; 29(9):423-5. PubMed ID: 1046827 [No Abstract] [Full Text] [Related]
36. [Massive metrorrhagia in a patient under warfarin anticoagulation. Rapid reversal with a concentrated prothrombin complex (Prothromplex Immuno TIM 4 600 IU)]. Fuentes Pradera MA; Suárez Delgado JM; Yanes Vidal G; Yerga Pozo G Rev Esp Anestesiol Reanim; 2006 Dec; 53(10):669-71. PubMed ID: 17302086 [No Abstract] [Full Text] [Related]
37. A case of sulphasalazine potentiating the hypoprothombinemic effect of warfarin resulting in bleeding. Hall S; Rindone JP J Clin Pharm Ther; 2011 Apr; 36(2):246-8. PubMed ID: 21366655 [TBL] [Abstract][Full Text] [Related]
38. [Antivitamin K. Introduction]. Larcan A Angeiologie; 1967; 19(5):33-5. PubMed ID: 5621970 [No Abstract] [Full Text] [Related]
40. A comparison of anticoagulation results of patients managed with narrow vs. standard international normalized ratio target ranges. Meier DJ; Seva S; Fay WP J Thromb Haemost; 2007 Jun; 5(6):1332-4. PubMed ID: 17403091 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]